STOCK TITAN
  1. Home
  2. News
  3. IMVT

Immunovant Inc - IMVT STOCK NEWS

IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Announces Positive IMVT-1402 Initial 600 mg MAD Results that Confirm Best-in-Class Potential
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant to Present at Upcoming Investor Conferences
conferences
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended September 30, 2023
earnings
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Announces Pricing of $450 Million Common Stock Financing
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Announces Proposed Offering of $300 Million of Common Stock
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Announces Positive Initial IMVT-1402 Phase 1 SAD and 300 mg Subcutaneous MAD Results
clinical trial
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant to Host Conference Call and Webcast to Report Initial IMVT-1402 Phase 1 Results on September 26, 2023
conferences clinical trial
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended June 30, 2023
earnings
IMPACT
SENTIMENT
IMVT : Nasdaq
Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023
earnings
Stock IMVT logo
Immunovant Inc

Nasdaq:IMVT

IMVT Rankings

#1362 Ranked by Market Cap
#39 Ranked by Stock Gains
N/A Ranked by Dividends

IMVT Stock Data

Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
New York

About IMVT

immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.